China’s National Medical Products Administration authorized the country’s first cetuximab biosimilar with the approval of Simcere Zaiming’s Enlituo (CMAB-009, cetuximab beta injection) in combination ...

PURPOSESquamous cell carcinoma of the head and neck (SCCHN) is the sixth most common cancer, with approximately 225,419 new cases with over 125,000 deaths annually in India. This trial compared the ...

Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) have a poor prognosis, particularly those whose disease has progressed on previous platinum ...

The standard treatment for head and neck cancer, cisplatin, can’t be given to some patients due to pre-existing conditions. A new study compares the efficacy of two alternatives: cetuximab, a ...

The FDA approved encorafenib, cetuximab, and mFOLFOX6 for mCRC with BRAF V600E mutation, based on the BREAKWATER trial results. The trial showed a 61% ORR for the combination therapy, compared to ...

The median overall survival (OS) of the avelumab plus cetuximab group was not reached (25.2‒NR) compared to the avelumab group which was 35.8 mo (18.6‒NR) HR 0.78 (0.34‒1.80) p = 0.279 The ...